Geron, StemCells trials tackle different approaches to spinal cord injuries

Two groundbreaking spinal cord trials led by Bay Area companies, both of which hit milestones in September, could make or break commercial stem cell therapies.
Although the trials are different in many ways, both are closely watched by stem cell advocates and opponents and could have implications for California’s stem cell research funding agency.